@article{CCO3564,
author = {Richard Simon},
title = {Biomarker based clinical trial design},
journal = {Chinese Clinical Oncology},
volume = {3},
number = {3},
year = {2014},
keywords = {},
abstract = {The established molecular heterogeneity of human cancers and the subsequent stratification of conventional diagnostic categories require the development of new paradigms for the development of a reliable basis for predictive medicine. We review clinical trial designs for the development of new therapeutics and predictive biomarkers to inform their use. We cover designs for a wide range of settings. At one extreme is the development of a new drug with a single biomarker and strong biological evidence that marker negative patients are unlikely to benefit from the new drug. At the other extreme are phase III clinical trials involving both genome-wide discovery and internal validation of a predictive classifier that identifies the patients most likely and unlikely to benefit from the new drug.},
issn = {2304-3873}, url = {https://cco.amegroups.org/article/view/3564}
}